ICER
-
Caught my eye, Generics, Healthcare Costs, ICER, Inflation Reduction Act, Medicaid, Medicare Negotiation, Medicare Part D, Orphan Drugs, State-based Reform, ValueCaught my eye — 03/07/25
Read more: Caught my eye — 03/07/25Tuesday morning, I spent the first half of the day convinced it was Wednesday, and yet, despite that mental setback, the rest of the week has flown by. Feels like a win. Killing me softly. Overall, glad to see the stories recognizing how the uncertainty of federal research dollars is impacting NIH summer internships, graduate…
-
Caught my eye, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Obesity, ValueCaught my eye — 2/14/25
Read more: Caught my eye — 2/14/25Roses are red. Violets are blue. I love health policy, how about you? Public Health Gap: This week a poll found that a quarter of Americans see healthcare access and affordability as their top public health concern and think it would be best solved on the federal level. Among Democrats, 32% had it as their…
-
Caught my eye — 1/24/25
Read more: Caught my eye — 1/24/25I am pretty sure January is actually the whole first half of the year. Bears and hibernation might have the right idea. Old Hat Already: I hit send last week and the Centers for Medicare & Medicaid Services (CMS) released the list of 2027 Medicare negotiated drugs. Overall it felt like just another announcement with…
-
Caught my eye — 12/13/24
Read more: Caught my eye — 12/13/24Methodology Matters. The Institute for Clinical and Economic Review (ICER) released their annual Unsupported Price Increase report and I find the whole process maddening. The inflationary metric they used was medical, not general (CPI-U). You might think that didn’t matter but it does. You know what medical inflation was? 0.48%. So anything over 2.48% increase…
-
Caught my eye — 11/15/24
Read more: Caught my eye — 11/15/24Broken Crystal Ball. Does the knowledge that RFK Jr might be heading up the Department of Health and Human Services get me any closer to guessing what might happen in the next 2 – 3 years for pharmaceutical health policy? Nope. But it wouldn’t seem like it would be good for innovation. NIH grants? Developing…
-
340B, Caught my eye, Drug Prices, Employers, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Reference Pricing, ValueCaught my eye — 5/10/24
Read more: Caught my eye — 5/10/24Back to back. Arnold Ventures put out the latest anti-pharma talking points (h/t Brian Reid) and here were two back to back – Here’s the problem, it really isn’t about the cost of drugs. I mean you could take that drug price and reduce it 98% and the 25% cost share would still be too…
-
Affordable Care Act, Healthcare Costs, ICER, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part D, State-based ReformCaught my eye — 4/12/24
Read more: Caught my eye — 4/12/24PDAB-adieu. This week Governor Youngkin vetoed a bill that would have established a prescription drug affordability board (PDAB) in the state. The PDAB would have had authority over state-sponsored and state-regulated health plans. Younkin said that the PDAB would have determined drug availability solely on cost rather than unique patient needs and the opinions of…
-
340B, Biosimilars, Copay Accumulators, ICER, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersNot on my 2023 Bingo Card
Read more: Not on my 2023 Bingo CardWe’re in that last work week before everyone dashes off. My own clients have headed for the hills (Short Hills?) and I’ve been baking and wrapping this week. It makes me appreciate the usual day to day of policy and reimbursement more than I would have thought. Next week I’ll pull out the vision boards…
-
Caught my eye — 9/29/23
Read more: Caught my eye — 9/29/23It’s not a vacation. Let’s start with federal employees; you deserve better. You often could get paid more elsewhere but you want to serve. And instead of saying thank you, Congress asks you to take a seat on the bench and (hopefully) get backpay. It feels awful and I am so sorry you have to…
Latest news
- Caught my eye — 03/28/25
- Caught my eye — 3/21/25
- Caught my eye — 3/14/25
- Caught my eye — 03/07/25
- Caught my eye — 2/28/25
Categories
- 340B (33)
- Affordable Care Act (4)
- Alzheimer's (5)
- Biosimilars (20)
- Caught my eye (61)
- Cell and Gene (1)
- Chevron Deference (2)
- CMMI (10)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (30)
- Drug shortages (8)
- DTC (2)
- Employers (7)
- Generics (5)
- Health Equity (3)
- Healthcare Costs (28)
- ICER (9)
- Importation (2)
- Inflation Reduction Act (45)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (6)
- Medicare Advantage (15)
- Medicare Negotiation (48)
- Medicare Part D (44)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (7)
- Obesity (20)
- On the Horizon (1)
- Orphan Drugs (3)
- Pharmacy Benefit Managers (28)
- Reference Pricing (5)
- State-based Reform (14)
- Supply Chain (1)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (4)
- Value (12)